Bicycle Therapeutics PLC (BCYC)

NASDAQ: BCYC · IEX Real-Time Price · USD
30.61
-0.90 (-2.86%)
At close: Dec 9, 2022 4:00 PM
30.00
-0.61 (-1.99%)
After-hours: Dec 9, 2022 4:08 PM EST
-2.86%
Market Cap 935.52M
Revenue (ttm) 15.05M
Net Income (ttm) -100.78M
Shares Out 29.68M
EPS (ttm) -2.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 101,092
Open 31.39
Previous Close 31.51
Day's Range 30.41 - 31.62
52-Week Range 12.08 - 61.5
Beta 0.79
Analysts Buy
Price Target 54.79 (+79.0%)
Earnings Date Nov 3, 2022

About BCYC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, ... [Read more]

Industry Biotechnology
IPO Date May 23, 2019
CEO Kevin Lee
Employees 119
Stock Exchange NASDAQ
Ticker Symbol BCYC
Full Company Profile

Financial Performance

In 2021, BCYC's revenue was $11.70 million, an increase of 12.58% compared to the previous year's $10.39 million. Losses were -$66.82 million, 31.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for BCYC stock is "Buy." The 12-month stock price forecast is 54.79, which is an increase of 78.99% from the latest price.

Price Target
$54.79
(78.99% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cel...

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

4 weeks ago - Business Wire

Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic ...

1 month ago - Business Wire

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic ...

1 month ago - Business Wire

Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

1 month ago - Business Wire

Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic ...

1 month ago - Business Wire

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular ...

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

2 months ago - Business Wire

Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

3 months ago - Business Wire

Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

3 months ago - Business Wire

Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

4 months ago - Business Wire

Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Propr...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

4 months ago - Business Wire

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journa...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

4 months ago - Business Wire

Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

4 months ago - Business Wire

Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjuga...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

6 months ago - Business Wire

Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

6 months ago - Business Wire

Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

6 months ago - Business Wire

Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

7 months ago - Business Wire

Bicycle Therapeutics reports promising BT8009 study results, shares tank 30%

Bicycle Therapeutics plc (NASDAQ: BCYC) is down 30% after the biotech firm pioneering novel and differentiated therapeutics class based on its bicyclin peptide tech announced preliminary first phase res...

7 months ago - Invezz

Here's Why Bicycle Therapeutics Stock Looks Ill Today

Lackluster clinical trial results for its lead candidate are to blame.

7 months ago - The Motley Fool

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar?

Bicycle Therapeutics PLC Sponsored ADR (BCYC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest ...

7 months ago - Zacks Investment Research

Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data

Shares of Bicycle Therapeutics Inc. BCYC, +24.54% tumbled 23.4% in premarket trading on Monday after the company shared interim data from a Phase 1 clinical trial for its urothelial-cancer treatment. Bi...

7 months ago - Market Watch

Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

7 months ago - Business Wire

Why Bicycle Therapeutics Stock Is Soaring Today

Bicycle Therapeutics plc (NASDAQ: BCYC) has announced interim Phase 1 results from the Phase 1/2 trial of BT8009, a second-generation BTC targeting Nectin-4, in patients with advanced solid tumors. The ...

8 months ago - Benzinga

Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

8 months ago - Business Wire

Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Ann...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

8 months ago - Business Wire

Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

8 months ago - Business Wire